Shirong Cao

Shirong Cao

Auto-generated profile, based on publicly available information

Shirong Cao

Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCShirong Cao
Shirong Cao
YPYu Pan
Yu Pan
ATAndrew S. Terker
Andrew S. Terker
JOJuan Pablo Arroyo Ornelas
Juan Pablo Arroyo Ornelas
YWYinqiu Wang
Yinqiu Wang
RHRaymond C Harris
Raymond C Harris
Fibrosis is the progressive accumulation of excess extracellular matrix and can cause organ failure. Fibrosis can affect nearly every organ including kidney and there is no specific treatment currently. Although Epidermal Growth Factor Receptor (EGFR) signaling pathway has been implicated in development of kidney fibrosis, underlying mechanisms by which EGFR itself mediates kidney fibrosis have not been elucidated. We find that EGFR expression increases in interstitial myofibroblasts in human and mouse fibrotic kidneys. Selective EGFR deletion in the fibroblast/pericyte population inhibits interstitial fibrosis in response to unilateral ureteral obstruction, ischemia or nephrotoxins. In vivo and in vitro studies and single-nucleus RNA sequencing analysis demonstrate that EGFR activation does not induce myofibroblast transformation but is necessary for the initial pericyte/fibroblast migration and proliferation prior to subsequent myofibroblast transformation by TGF-ß or other profibrotic factors. These findings may also provide insight into development of fibrosis in other organs and in other conditions.

9 April 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CVCaitlyn Vlasschaert
Caitlyn Vlasschaert
YPYang Pan
Yang Pan
JCJianchun Chen
Jianchun Chen
EAElvis Akwo
Elvis Akwo
VRVarun Rao
Varun Rao
TKTanika Kelly
Tanika Kelly
Key Points: Non- DNMT3A clonal hematopoiesis of indeterminate potential was associated with CKD progression in a meta-analysis of 5654 individuals with CKD. In an adenine-induced CKD mouse model, Tet2 -clonal hematopoiesis of indeterminate potential was linked to lower GFR, increased kidney inflammation, tubular injury, and fibrosis. Background: Clonal hematopoiesis of indeterminate potential (CHIP) is a common inflammatory condition of aging that causes myriad end-organ damage. CHIP has been associated with incident AKI and kidney function decline in the general population, particularly mutations in CHIP genes other than DNMT3A (termed non- DNMT3A CHIP). Previous studies of CHIP in individuals with CKD had limited sample sizes and conflicting findings. Methods: We examined CHIP and CKD progression in four CKD cohorts ( N =5654): the Chronic Renal Insufficiency Cohort, the African American Study of Kidney Disease, individuals with CKD from the BioVU biorepository, and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events. Primary outcomes were incident CKD progression (50% eGFR decline or kidney failure) and eGFR slope over time. In addition, kidney function and pathology were assessed in a Tet2 -CHIP mouse model of CKD induced by dietary adenine. Results: Across all cohorts, the average age was 66±11 years, with an average baseline eGFR of 43±15 ml/min per 1.73 m 2 , and 24% had CHIP. After meta-analysis, non- DNMT3A CHIP was associated with a 64% higher relative risk of incident CKD progression (hazard ratio, 1.64; 95% confidence interval, 1.00 to 2.68), with the strongest effect observed in individuals with baseline eGFR 30–60 ml/min per 1.73 m 2 (hazard ratio, 1.85; 95% confidence interval, 1.18 to 2.90). Non- DNMT3A CHIP carriers also exhibited a faster eGFR decline ( β , −0.62±0.28 ml/min per 1.73 m 2 per year; P = 0.03). In a dietary adenine mouse model of CKD, Tet2 -CHIP was associated with lower GFR as well as greater kidney inflammation, tubular injury, and tubulointerstitial fibrosis. Conclusions: Non- DNMT3A CHIP was associated with CKD progression among individuals with CKD. Furthermore, Tet2 -CHIP mouse models support a causal role in kidney injury.

7 July 2021 in Diabetes
Verified
Journal Article
Open access
PDF file
YWYinqiu Wang
Yinqiu Wang
ANAolei Niu
Aolei Niu
YPYu Pan
Yu Pan
SCShirong Cao
Shirong Cao
ATAndrew S. Terker
Andrew S. Terker
RHRaymond C Harris
Raymond C Harris
Podocyte injury is important in development of diabetic nephropathy (DN). Although several studies have reported single cell-based RNA-seq of podocytes in type 1 DN (T1DN), the podocyte translating mRNA profile in type 2 DN (T2DN) has not been previously compared to that of T1DN. We analyzed the podocyte translatome in T2DN in podocin-Cre; Rosa26fsTRAP; eNOS-/-; db/db mice and compared it to streptozotocin-induced T1DN in podocin-Cre; Rosa26fsTRAP; eNOS-/- mice utilizing Translating Ribosome Affinity Purification (TRAP) and RNA-seq. Over 125 genes were highly enriched in the podocyte ribosome. More podocyte TRAP genes were differentially expressed in T2DN compared to T1DN. TGF-β signaling pathway genes were upregulated while MAPK pathway genes were downregulated only in T2DN while ATP binding and cAMP-mediated signaling genes were downregulated only in T1DN. Genes regulating actin filament organization and apoptosis increased while genes regulating VEGFR signaling and glomerular basement membrane components decreased in both type 1 and type 2 diabetic podocytes. A number diabetes-induced genes not previously been linked to podocyte injury were confirmed in both mouse and human DN. Differences and similarities in the podocyte translatome in T2DN and T1DN can identify factors underlying the pathophysiology of DN and novel therapeutic targets to treat diabetes-induced podocyte injury.

2 September 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
JCJianchun Chen
Jianchun Chen
FPFen-Fen Peng
Fen-Fen Peng
MJMengdi Jiang
Mengdi Jiang
SCShirong Cao
Shirong Cao
CZChen Zhao
Chen Zhao
RHRaymond C Harris
Raymond C Harris
Key Points: Upregulation and colocalization of EGF receptor and SOX9 were exhibited in injured renal proximal tubule epithelial cells (RPTCs). Genetic or pharmacologic inhibition of EGF receptor activation in mice blocked SOX9 upregulation in the ischemic injured RPTCs. Inhibition of yes-associated protein/transcriptional coactivator with PDZ-binding motif–transcriptional enhanced associate domain in mice or cultured RPTCs blocked SOX9 upregulation in response to ischemic AKI or EGF treatment. Background: In surviving renal proximal tubule cells (RPTCs) after AKI, the induction of SOX9 expression plays a crucial role in promoting kidney repair. However, persistent upregulation of SOX9 in RPTCs contributes to the development of CKD. The molecular mechanisms underlying SOX9 induction in response to kidney injury are not completely understood. We and others have previously reported that the activation of EGF receptor (EGFR) in RPTCs can accelerate kidney recovery from ischemic injury, but persistent EGFR activation leads to tubulointerstitial fibrosis. Methods: We examined SOX9 and EGFR expression in renal tubular epithelial cells of patients with acute tubular injury or early stages of chronic allograft nephropathy. We investigated the role of EGFR activation in regulating SOX9 upregulation in injured RPTCs using different mouse models. We further confirmed the underlying mechanism by which EGFR activation upregulates SOX9 expression in cultured human RPTCs. Results: Elevation and colocalization of SOX9 and EGFR expression were detected in renal tubular epithelial cells of patients with acute tubular injury or early stages of chronic allograft nephropathy. Overexpression of human heparin-binding EGF in RPTC of mice led to increased SOX9 expression, which was abolished when these mice were crossed with EGFR tyrosine kinase–deficient waved2 mice. Genetic or pharmacologic inhibition of EGFR resulted in decreased SOX9 expression in renal tubular cells in response to ischemic AKI. Mechanistically, ischemic AKI activates proximal tubule EGFR, leading to the activation of Akt–yes-associated protein/transcriptional coactivator with PDZ-binding motif–transcriptional enhanced associate domain pathway and the subsequent induction of SOX9. Conclusions: EGFR activation is crucial for SOX9 expression in RPTCs after AKI.

6 August 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MTMing-Tsun Tsai
Ming-Tsun Tsai
MJMengdi Jiang
Mengdi Jiang
YPYu Pan
Yu Pan
SCShirong Cao
Shirong Cao
YWYinqiu Wang
Yinqiu Wang
RHRaymond C Harris
Raymond C Harris
Key Points: Cyclooxygenase 2 expression increased in kidney fibroblasts in response to a fibrotic stimulus. Fibroblast cyclooxygenase 2–mediated PGE2 promoted an anti-inflammatory, proreparative phenotype in macrophages by activating the PGE2 receptor EP4. Selective deletion of fibroblast cyclooxygenase 2 promoted a proinflammatory macrophage phenotype, which exacerbated kidney fibrosis. Background: During progressive kidney injury, pericytes and resident fibroblasts migrate, proliferate, and differentiate into myofibroblasts, which are the major source of extracellular matrix deposition. Both interstitial fibroblasts and macrophages contribute to kidney fibrosis and coexist within the fibrotic niche. However, the potential interaction between fibroblasts and macrophages and its role in kidney fibrosis remains incompletely understood. Previous studies have indicated a role for kidney prostaglandins to limit fibroblast activity and myofibroblast transformation. Methods: Inducible PDGFR β -Cre mice were crossed to the indicated floxed mice to selectively delete either cyclooxygenase 2 (COX-2) or the PGE2 receptors EP2 and EP4. Unilateral ureteral obstruction was used as a model of progressive kidney fibrosis. Results: Selective deletion of cyclooxygenase-2 expression in fibroblasts (FibCOX-2−/−) increased kidney fibrosis in association with kidney macrophages with a proinflammatory and profibrotic phenotype. The highest differentially expressed gene in these macrophages was the profibrotic factor SPP1/osteopontin, and deletion of kidney macrophages with clodronate inhibited kidney expression of SPP1 and ameliorated fibrosis in FibCOX2−/− mice. Conclusions: Our findings suggest that fibroblast COX-2 protects against progressive kidney fibrosis, potentially through a regulatory interplay that modulates the surrounding macrophage phenotype during chronic kidney injury.

24 February 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
GBGema Bolas
Gema Bolas
CBCorina M. Borza
Corina M. Borza
FBFabian Bock
Fabian Bock
XDXinyu Dong
Xinyu Dong
OHOscar Hanson
Oscar Hanson
APAmbra Pozzi
Ambra Pozzi
Key Points: Discoidin domain receptor 1 (DDR1) translocated to the mitochondria of proximal tubule cells after AKI. DDR1 contributed to AKI by promoting the production of mitochondrial reactive oxygen species and cell apoptosis. Mechanistically, DDR1 translocated to mitochondria by interacting with Hsp60 and promoted oxidative stress by regulating phosphorylation of p66Shc. Background: Mitochondrial damage with overproduction of mitochondrial reactive oxygen species (mtROS) and apoptosis is a hallmark of AKI. Discoidin domain receptor 1 (DDR1) is a collagen receptor tyrosine kinase that contributes to AKI. Mass spectrometry analysis of DDR1-interacting proteins identified several mitochondrial proteins, suggesting that DDR1 associated with mitochondria. Thus, we analyzed whether DDR1 translocated to mitochondria and promoted mitochondrial dysfunction after AKI. Methods: We analyzed DDR1 localization in kidneys of patients with AKI and mice after ischemia/reperfusion–induced AKI. To determine whether mitochondrial DDR1 (mtDDR1) regulated mitochondrial functions, we generated kidney cells expressing wild-type or a kinase dead DDR1. Then, we investigated the location of wild-type or mutated DDR1 on collagen stimulation, the steps involved in DDR1 mitochondrial translocation, and the contribution of mtDDR1 in regulating mtROS production and apoptosis. Results: mtDDR1 was detected in injured human and mice kidneys, and collagen-activated DDR1 translocated to the mitochondria where it increased mtROS production and tubule cell apoptosis. Collagen-activated DDR1 translocated to the outer membrane of mitochondria through its association with the chaperone mtHsp60 and induced oxidative stress and apoptosis by promoting tyrosine phosphorylation of p66Shc, a regulator of the cellular redox state and apoptosis. Moreover, cells expressing a kinase dead DDR1, treated with a DDR1 inhibitor, or expressing p66Shc mutated in the DDR1-targeted phosphorylation sites had reduced mtROS and apoptosis. Conclusions: We describe a novel noncanonical pathway whereby activated DDR1 translocates to the mitochondria to promote oxidative stress and cell apoptosis.